Furthermore, investigation of the ER-specific and non-specific interactions of these probes in breast cancer cells and tumors and in muscle tissue, as well as the competition with tamoxifen emphasized the advantage of EPTA-Gd over TPTA-Gd as an ER-targeted CA in vivo. The gene discussed is ESR1; the disease is breast cancer.